4o09: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
{{STRUCTURE_4o09| PDB=4o09 | SCENE= }} | |||
===Identification of novel HSP90 / isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington s disease=== | |||
{{ABSTRACT_PUBMED_24673104}} | |||
==Function== | |||
[[http://www.uniprot.org/uniprot/HS90A_HUMAN HS90A_HUMAN]] Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle that is linked to its ATPase activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function.<ref>PMID:15937123</ref> <ref>PMID:11274138</ref> | |||
==About this Structure== | |||
[[4o09]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4O09 OCA]. | |||
==Reference== | |||
<ref group="xtra">PMID:024673104</ref><references group="xtra"/><references/> | |||
[[Category: Ernst, J T.]] | |||
[[Category: Zuccola, H J.]] | |||
[[Category: Chaperone]] | |||
[[Category: Chaperone-chaperone inhibitor complex]] |